BMY - Bristol-Myers Squibb Company
| Previous Close | 58.900 |
| Open | 57.500 |
| Bid | 56.400 x 800 |
| Ask | 56.390 x 1000 |
| Day's Range | 56.100 - 57.530 |
| 52 Week Range | 49.960 - 70.050 |
| Volume | 5,550,409 |
| Avg. Volume | 5,803,563 |
| Market Cap | 91.85B |
| Beta (3Y Monthly) | 1.16 |
| PE Ratio (TTM) | 250.16 |
| EPS (TTM) | 0.225 |
| Earnings Date | Oct 25, 2018 |
| Forward Dividend & Yield | 1.60 (2.78%) |
| Ex-Dividend Date | 2018-10-04 |
| 1y Target Est | 61.59 |
Markit•4 hours agoSee what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co NYSE:BMY
- Business Wire•yesterday
Bristol-Myers Squibb to Showcase Immunoscience Research and Biomarker-Guided Treatment Approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
- Growing body of evidence, including real-world studies, points to the clinical significance of anti-citrullinated protein antibody as a biomarker of poor prognosis in pati
Market Realist•2 days agoHow Nektar Therapeutics Is Positioned In October
Nektar Therapeutics (NKTR) is focused on developing a strong pipeline of product candidates that utilize its polymer conjugate technology platforms. Its research pipeline includes investigational drugs for cancer, autoimmune diseases, and chronic pain. Nektar Therapeutics generated revenues of $1.09 billion in the second quarter of 2018.
American City Business Journals•3 days agoHealth Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners
A look at who's moving, who's growing and who's dealing in the Bay Area's health care and life sciences space.
- Zacks•3 days ago
Bristol-Myers Reports Disappointing Data From SCLC Study
Bristol-Myers??? (BMY) late-stage study on blockbuster immuno-oncology drug, Opdivo for the treatment of SCLC fails.
- Zacks•3 days ago
Zacks.com highlights: Bristol-Myers Squibb, Celanese, Ternium S.A. and Mettler-Toledo International
Zacks.com highlights: Bristol-Myers Squibb, Celanese, Ternium S.A. and Mettler-Toledo International
- Market Realist•3 days ago
Novartis: What to Expect from Q3 Earnings on October 18
Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.
- Zacks•6 days ago
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
- Zacks•6 days ago
Bristol-Myers Inks Deal and Invests $12 Million in Compugen
Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.
- Zacks•6 days ago
4 Top Stocks to Buy for Superb Earnings Growth
We select four stocks that have striking earnings growth and positive estimate revisions.
- Reuters•6 days ago
Bristol-Myers' Opdivo fails to meet lung cancer study goal
Bristol-Myers Squibb Co said on Friday that its blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy. The drug failed to extend overall survival in patients suffering from small cell lung cancer, an aggressive form of the disease, when compared to patients already on chemotherapy. Opdivo has already been approved to treat several forms of cancer, including skin and lung cancer.
- MarketWatch•6 days ago
Bristol-Myers says trial of small cell lung cancer treatment failed to meet main goal
Bristol-Myers Squibb Co. said Friday a late-stage trial of a treatment for small cell lung cancer failed to meet its main goal. The drug company said the Phase 3 study called CheckMate-331 evaluating its opdivo in patients with the disease who relapsed following platinum-based chemotherapy failed to meet its primary endpoint of overall survival. "Small cell lung cancer is a highly aggressive disease in which significant unmet need remains," said Sabine Maier, development lead, thoracic cancers, at Bristol-Myers Squibb. "We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer." Shares were slightly higher premarket, but have fallen 6.1% in 2018, while the S&P 500 has gained 2.1%.
- Business Wire•6 days ago
Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer
Bristol-Myers Squibb Company today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo versus the current standard of care, topotecan or amrubicin , in patients with small cell lung cancer who relapsed following platinum-based chemotherapy.
Market Realist•7 days agoWhat to Expect from Johnson & Johnson’s Q3 2018 Earnings
Johnson & Johnson (JNJ) plans to report its third-quarter earnings on October 16. Wall Street analysts expect JNJ to register adjusted EPS of $2.03 in the third quarter, representing YoY (year-over-year) growth of ~6.7%. In comparison, the company reported second-quarter adjusted EPS of $2.10.
- Market Realist•7 days ago
How Analysts View Alexion Pharmaceuticals Stock in October
In October, 18 analysts are covering Alexion Pharmaceuticals (ALXN) stock. Five of them have recommended a “strong buy,” 11 have recommended a “buy,” and two have recommended a “hold.”
- MarketWatch•7 days ago
Compugen's stock shoots up after Bristol-Myers to pay 52% premium for equity stake
Shares of Compugen Ltd. shot up 17% in premarket trade Thursday, after Bristol-Myers Squibb Co. said it will make a $12 million equity investment as part of a collaboration on a cancer treatment. As part of the agreement, Bristol-Myers will buy about 2.4 million shares at $4.95 a share, which is 52% above Wednesday's closing price of $3.25. The companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's investigational anti-PVRIG antibody, COM701, in combination with Bristol-Myers' immune checkpoint inhibitor Opdivo, in patients with advanced solid tumors. Bristol-Myers' stock fell 1.3% ahead of the open. Year to date, Compugen's stock has soared 30% through Wednesday, while Bristol-Myers shares have slipped 0.8% and the S&P 500 has gained 4.2%.
- Reuters•7 days ago
Bristol-Myers to invest in Compugen, collaborate in clinical trials
Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumours. The trials will evaluate the safety and tolerability of Compugen’s COM701, an investigational antibody, in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor Opdivo. In conjunction with the collaboration, Bristol-Myers Squibb will invest $12 million in Compugen, purchasing 2,424,243 shares - equal to a 4.1 percent stake - at $4.95 each.
- Business Wire•7 days ago
Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
Bristol-Myers Squibb Company and Compugen today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s programmed death-1 immune checkpoint inhibitor Opdivo , in patients with advanced solid tumors.
- PR Newswire•7 days ago
Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
NEW YORK and HOLON, Israel , Oct. 11, 2018 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration ...
- Zacks•8 days ago
Novartis Presents Positive Data on Sickle Cell Disease Drug
Novartis (NVS) announces positive results from a post hoc analysis of the phase II study, SUSTAIN, on pipeline candidate, crizanlizumab, being published in the American Journal of Hematology.
Market Realist•8 days agoAlexion Pharmaceuticals’ Operational Performance
Alexion Pharmaceuticals’ (ALXN) total operating expenses increased from $602.4 million in the second quarter of 2017 to $1.35 billion in the second quarter of 2018. It generated operating income of $226.7 million in the second quarter of 2017. In the second quarter of 2018, it had an operating loss of $400.1 million.
Market Realist•8 days agoHow Alexion Pharmaceuticals Is Positioned in October
Alexion Pharmaceuticals (ALXN) is a leader in complement inhibition. It focuses on hematology, nephrology, neurology, and metabolic disorders. In this series, we’ll explore its financials, valuation metrics, latest developments, and analyst recommendations.
Market Realist•8 days agoAnalyzing Alexion Pharmaceuticals’ Top-Line Trends
Alexion Pharmaceuticals’ (ALXN) revenues increased $132.3 million to $1.04 billion in the second quarter of 2018 compared to the second quarter of 2017. For fiscal 2018 and fiscal 2019, Alexion Pharmaceuticals is expected to generate revenues of $4.04 billion and $4.72 billion, respectively, compared to $3.55 billion in fiscal 2017. Fiscal 2018 gross margins for its peers Abbott Laboratories (ABT), Amgen (AMGN), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), and Pfizer (PFE) are expected to be 59.10%, 85.94%, 70.09%, 69.64%, and 79.21%, respectively.
Market Realist•8 days agoHow Bristol-Myers Squibb’s Valuation Metrics Look in October
Of the total 18 analysts covering Bristol-Myers Squibb (BMY) in October, seven analysts have given the stock a “buy” or higher rating, ten analysts have given it a “hold” rating, and one analyst has given it a “sell” rating. The mean rating for Bristol-Myers Squibb stock is 2.44 with a target price of $60.75.
Market Realist•8 days agoWhat Bristol-Myers Squibb’s Operational Performance Indicates
How Is Bristol-Myers Squibb Positioned in October 2018? Bristol-Myers Squibb (BMY) incurred a cost of product sales of $1.63 billion in the second quarter of 2018 as compared with $1.57 billion in the second quarter of 2017.
